Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …
Biotechnology
US, Newark [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Rain Therapeutics Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDRain Therapeutics Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Rain Therapeutics Inc..
If you want to see a demo, head over to the financial segments of AAPL